Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis

• Published in: Arthritis research & therapy Vol. 23; no. 1; p. 118
• Main Authors: Klotsche, Jens, Klein, Ariane, Niewerth, Martina, Hoff, Paula, Windschall, Daniel, Foeldvari, Ivan, Haas, Johannes-Peter, Horneff, Gerd, Minden, Kirsten
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.04.2021; BioMed Central; BMC
• Subjects: Arthritis; Disease flare; Drug therapy; Effectiveness; Etanercept; Inactive disease; Juvenile idiopathic arthritis; Patient outcomes; Patients; Pediatric research; Pediatrics; Physicians; Regression (Disease); Remission (Medicine); Rheumatoid arthritis in children; Rheumatology; Teenagers; Tumor necrosis factor-TNF; Window of opportunity; Germany; Effectiveness; Etanercept; Window of opportunity; Inactive disease; Remission; Disease flare; Juvenile idiopathic arthritis

To determine (i) correlates for etanercept (ETA) discontinuation after achieving an inactive disease and for the subsequent risk of flare and (ii) to analyze the effectiveness of ETA in the re-treatment after a disease flare. Data from two ongoing prospective registries, BiKeR and JuMBO, were used f...